Key result
Hydralazine plus isosorbide dinitrate remains a valuable HFrEF therapy in specific patient populations.
Why the study?
Although the role of hydralazine and isosorbide dinitrate in HFrEF has been overshadowed over time by neurohumoral antagonists, it remains clinically significant, particularly in certain populations.
Does hydralazine and isosorbide dinitrate improve clinical outcomes in patients with heart failure with reduced ejection fraction?
Does hydralazine and isosorbide dinitrate improve clinical outcomes in patients with heart failure with reduced ejection fraction?
This review highlights the historical evidence, pharmacological mechanisms, and current guideline recommendations supporting the use of hydralazine and isosorbide dinitrate in specific HFrEF populations, while identifying significant gaps in contemporary evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fernandes-Silva et al. (2024) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Hydralazine and isosorbide dinitrate (H-ISDN) was evaluated. The combination of hydralazine and isosorbide dinitrate remains a significant therapy for heart failure with reduced ejection fraction, particularly in certain populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: